{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T13:51:17Z","timestamp":1785333077453,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.nmd.2021.02.010","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T02:29:06Z","timestamp":1614047346000},"page":"512-518","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Efficacy and safety of tacrolimus as long-term monotherapy for myasthenia gravis"],"prefix":"10.1016","volume":"31","author":[{"given":"Kumi","family":"Itani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reika","family":"Wate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Morise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takenobu","family":"Kunieda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Takenouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Yakushiji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Kusaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2021.02.010_bib0001","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2021.02.010_bib0002","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2021.02.010_bib0003","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of Myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2021.02.010_bib0004","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1212\/WNL.26.8.729","article-title":"Long-term administration of corticosteroids in myasthenia gravis","volume":"26","author":"Mann","year":"1976","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2021.02.010_bib0005","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1212\/WNL.34.2.170","article-title":"Myasthenia gravis: prolonged treatment with steroids","volume":"34","author":"Sghirlanzoni","year":"1984","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2021.02.010_bib0006","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1600-0404.1991.tb04899.x","article-title":"Effectiveness of steroid treatment in myasthenia gravis: a retrospective study","volume":"84","author":"Cosi","year":"1991","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.nmd.2021.02.010_bib0007","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000116785","article-title":"Long-term results of corticosteroid therapy in patients with myasthenia gravis","volume":"32","author":"Evoli","year":"1992","journal-title":"Eur Neurol"},{"key":"10.1016\/j.nmd.2021.02.010_bib0008","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ana.410150316","article-title":"Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients","volume":"15","author":"Pascuzzi","year":"1984","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2021.02.010_bib0009","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1054\/jocn.2001.0907","article-title":"Low-dose tacrolimus for intractable myasthenia gravis","volume":"9","author":"Yoshikawa","year":"2002","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.nmd.2021.02.010_bib0010","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/mus.10472","article-title":"Clinical study of FK506 in patients with myasthenia gravis","volume":"28","author":"Konishi","year":"2003","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2021.02.010_bib0011","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/mus.10018","article-title":"Successful treatment of myasthenia gravis with tacrolimus","volume":"25","author":"Evoli","year":"2002","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2021.02.010_bib0012","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/jnnp.2004.042176","article-title":"Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus)","volume":"76","author":"Konishi","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nmd.2021.02.010_bib0013","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000085833","article-title":"Efficacy of low-dose FK506 in the treatment of myasthenia gravis-a randomized pilot study","volume":"53","author":"Nagane","year":"2005","journal-title":"Eur Neurol"},{"key":"10.1016\/j.nmd.2021.02.010_bib0014","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.clineuro.2004.07.013","article-title":"Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study","volume":"107","author":"Ponseti","year":"2005","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.nmd.2021.02.010_bib0015","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1212\/01.WNL.0000160392.32894.6D","article-title":"Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis","volume":"64","author":"Ponseti","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2021.02.010_bib0016","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1196\/annals.1405.000","article-title":"Tacrolimus for myasthenia gravis: a clinical study of 212 patients","volume":"1132","author":"Ponseti","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.nmd.2021.02.010_bib0017","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jocn.2004.12.008","article-title":"Tacrolimus in refractory patients with myasthenia gravis: coadministration and tapering of oral prednisolone","volume":"13","author":"Shimojima","year":"2006","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.nmd.2021.02.010_bib0018","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jns.2006.03.010","article-title":"Long-term therapeutic efficacy and safety of low-dose tacrolimus (FK506) for Myasthenia gravis","volume":"247","author":"Tada","year":"2006","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.nmd.2021.02.010_bib0019","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jns.2017.05.060","article-title":"A multicenter prospective observational study on the safety and efficacy of tacrolimus in patients with myasthenia gravis","volume":"379","author":"Ahn","year":"2017","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.nmd.2021.02.010_bib0020","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3349\/ymj.2019.60.7.633","article-title":"Long-term safety and efficacy of tacrolimus in myasthenia gravis","volume":"60","author":"Kim","year":"2019","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.nmd.2021.02.010_bib0021","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1136\/jnnp-2011-300148","article-title":"Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis","volume":"82","author":"Yoshikawa","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nmd.2021.02.010_bib0022","doi-asserted-by":"crossref","first-page":"576","DOI":"10.5692\/clinicalneurol.51.576","article-title":"Standard treatment for late-onset myasthenia gravis in Japan","volume":"51","author":"Motomura","year":"2011","journal-title":"Rinsho Shinkeigaku"},{"key":"10.1016\/j.nmd.2021.02.010_bib0023","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1212\/01.wnl.0000312373.67493.7f","article-title":"A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis","volume":"71","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2021.02.010_bib0024","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1749-6632.2012.06817.x","article-title":"The myasthenia gravis-specific activities of daily living profile","volume":"1274","author":"Muppidi","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.nmd.2021.02.010_bib0025","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1159\/000347068","article-title":"Tacrolimus monotherapy: a promising option for ocular myasthenia gravis","volume":"69","author":"Yagi","year":"2013","journal-title":"Eur Neurol"},{"key":"10.1016\/j.nmd.2021.02.010_bib0026","first-page":"453","article-title":"Tacrolimus monotherapy for initial immunosuppressive treatment of myasthenia gravis","volume":"30","author":"Fujita","year":"2013","journal-title":"Neurol Therap."},{"key":"10.1016\/j.nmd.2021.02.010_bib0027","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/0167-5699(92)90111-J","article-title":"The mechanism of action of cyclosporine A and FK506","volume":"13","author":"Schreiber","year":"1992","journal-title":"Immunol Today"},{"key":"10.1016\/j.nmd.2021.02.010_bib0028","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/mus.21462","article-title":"Factors associated with response to calcineurin inhibitors in myasthenia gravis","volume":"41","author":"Nagane","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2021.02.010_bib0029","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.nmd.2012.11.003","article-title":"Prednisolone-sparing effect of cyclosporin A therapy for very elderly patients with myasthenia gravis","volume":"23","author":"Nakamura","year":"2013","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2021.02.010_bib0030","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/cen3.12180","article-title":"Japanese clinical guidelines for myasthenia gravis: putting into practice","volume":"6","author":"Murai","year":"2015","journal-title":"Clin Exp Neuroimmunol"},{"key":"10.1016\/j.nmd.2021.02.010_bib0031","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1212\/WNL.55.1.7","article-title":"Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology","volume":"55","author":"Gronseth","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2021.02.010_bib0032","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/ene.13189","article-title":"Adequate tacrolimus concentration for myasthenia gravis treatment","volume":"24","author":"Kanai","year":"2017","journal-title":"Eur J Neurol"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896621000389?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896621000389?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:10:45Z","timestamp":1760775045000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896621000389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0960896621000389"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2021.02.010","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of tacrolimus as long-term monotherapy for myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2021.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}